Welcome to our dedicated page for Larimar Therapeutics news (Ticker: LRMR), a resource for investors and traders seeking the latest updates and insights on Larimar Therapeutics stock.
Larimar Therapeutics, Inc. develops treatments for complex rare diseases, with its lead program, nomlabofusp, focused on Friedreich’s ataxia. Nomlabofusp is a subcutaneously administered recombinant fusion protein designed to deliver frataxin to mitochondria, and company updates frequently address clinical data, frataxin measurement, FDA interactions and regulatory designations tied to that program.
Recurring LRMR news also covers operating and financial results, equity financing activity, corporate presentations and research publications related to its intracellular delivery platform. The company’s disclosures connect program development with capital needs, rare-disease regulatory pathways and the broader use of fusion proteins for diseases involving intracellular bioactive-compound deficiencies.
Larimar Therapeutics, Inc. (Nasdaq:LRMR) has announced significant advancements following its merger with Chondrial and Zafgen, including a completed $80 million private placement financing. The company has resumed its Phase 1 clinical trial for CTI-1601, targeting Friedreich’s ataxia, and received a positive opinion for orphan drug designation from the EMA. In the second quarter of 2020, Larimar reported a net loss of $11.3 million, with R&D expenses rising to $8.9 million due to increased development activities. The company holds approximately $113.7 million in cash and equivalents.
Larimar Therapeutics (Nasdaq:LRMR) has initiated the third cohort dosing in its Phase 1 clinical trial for CTI-1601, targeting Friedreich’s ataxia (FA). The trial, which encountered delays due to COVID-19, aims to assess the safety and tolerability of this recombinant fusion protein. To date, two cohorts have completed the trial, with topline results expected in early 2021. CTI-1601 has received multiple FDA designations, underscoring its potential as the first frataxin replacement therapy for FA, which currently has no approved treatments.
Larimar Therapeutics, Inc. (Nasdaq:LRMR) announced that Dr. Carole Ben-Maimon, President and CEO, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 4:30 p.m. EDT. The presentation will focus on the company’s advancements in developing treatments for complex rare diseases such as Friedreich’s ataxia. Interested investors can access a live audio webcast from the Investors section of Larimar’s website, which will also feature an archived version available for 30 days post-event.